Novartis Ag

Henrik Moebitz

Mark G Bock

Konstanze Hurth

Susanta Samajdar

Ramulu Poddutoori

Nicolas Soldermann

Sunil Kumar Panigrahi

Pascal Furet

Giorgio Caravatti

Frederic Zecri

Clive McCarthy

Sylvie Chamoin

Chetan Pandit

Ian Lewis

Alexander Baxter Smith

Dinesh Chikkanna

Romain Wolf

Karen Kammertoens

Klemens Hogenauer

Aleksandar Stojanovic

Jean-Michel Rene Rondeau

Heinrich Rueeger

Rainer Machauer

Marina Tintelnot-Blomley

Siem Jacob Veenstra

Venkateshwar Rao Gummadi

Christoph Gaul

Olivier Rogel

Saumitra Sengupta

Samuel Hintermann

Rainer Martin Lueoend

Emmanuelle Briard

Sébastien Jacquier

Ramulu Poddutorri

Zhenxing Du

Hansjoerg Lehmann

Mark Gary Bock

The present invention relates to compounds of formula I: 

Compounds and compositions as inhibitors of MEK

Provided are substituted quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein R, R, R, R, Rand L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases. 

Substituted quinazolin-4-one derivatives

The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R, R, Rand Rare as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R, R, R, R, R, R, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided. 

[object Object]

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases (e.g., cancer and inflammation). 

Heterocyclic sulfonamide derivatives

The present invention relates to compounds of Formula I where R, R, X, R, R, W, R, R, and Rare as defined herein as well as pharmaceutically acceptable salts thereof. The compounds have been shown to act as MEK inhibitors which may be useful in the treatment of hyperproliferative diseases, like cancer and inflammation.

The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors

Growing community of inventors

Freiburg, Germany

Henrik Moebitz